Abstract
Two of the main pathological hallmarks of Alzheimers disease (AD) are neuritic plaques and neurofibrillary tangles. Significant evidence supports a critical and probable causative role of βamyloid (Aβ) plaque formation. Since neuroprotective treatments are typically most effective at early stages of injury, the detection and measurement of Aβ load in living brain should be performed at early and perhaps even presymptomatic stages of AD. Two primary targets of molecular imaging research with positron emission tomography (PET) are to develop surrogate markers (radioligands) for assessing disease progression and for monitoring the efficacy of developmental therapeutics. Here, we review the current status of radioligand development for PET imaging of Aβ aggregates. General structure-activity relationships have emerged, including the identification of at least three different ligand binding sites in various Aβ aggregates and recognition of the general structural requirements for ligand binding at each site. Also a few radioligands applicable to imaging Aβ plaques in living human brain with positron emission tomography (PET) have emerged, including [11C]PIB, [11C]SB- 13 and [18F]FDDNP.
Keywords: PET imaging, β-amyloid, radioligand, assay, Alzheimer's disease
Current Medicinal Chemistry
Title: Radioligand Development for PET Imaging of β-Amyloid (Aβ)-Current Status
Volume: 14 Issue: 1
Author(s): Lisheng Cai, Robert B. Innis and Victor W. Pike
Affiliation:
Keywords: PET imaging, β-amyloid, radioligand, assay, Alzheimer's disease
Abstract: Two of the main pathological hallmarks of Alzheimers disease (AD) are neuritic plaques and neurofibrillary tangles. Significant evidence supports a critical and probable causative role of βamyloid (Aβ) plaque formation. Since neuroprotective treatments are typically most effective at early stages of injury, the detection and measurement of Aβ load in living brain should be performed at early and perhaps even presymptomatic stages of AD. Two primary targets of molecular imaging research with positron emission tomography (PET) are to develop surrogate markers (radioligands) for assessing disease progression and for monitoring the efficacy of developmental therapeutics. Here, we review the current status of radioligand development for PET imaging of Aβ aggregates. General structure-activity relationships have emerged, including the identification of at least three different ligand binding sites in various Aβ aggregates and recognition of the general structural requirements for ligand binding at each site. Also a few radioligands applicable to imaging Aβ plaques in living human brain with positron emission tomography (PET) have emerged, including [11C]PIB, [11C]SB- 13 and [18F]FDDNP.
Export Options
About this article
Cite this article as:
Cai Lisheng, Innis B. Robert and Pike W. Victor, Radioligand Development for PET Imaging of β-Amyloid (Aβ)-Current Status, Current Medicinal Chemistry 2007; 14 (1) . https://dx.doi.org/10.2174/092986707779313471
DOI https://dx.doi.org/10.2174/092986707779313471 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcranial Magnetic Stimulation in Schizophrenia: The Contribution of Neuroimaging
Current Topics in Medicinal Chemistry Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Invasive and Non-Invasive Electrical Neuromodulation in Trigeminal Nerve Neuralgia: A Systematic Review and Meta-Analysis
Current Neuropharmacology Catatonia: A Brief Update
Current Psychiatry Reviews Neurokinin-1 (NK<sub>1</sub>) receptor antagonists as possible therapeutics for psychostimulant use disorders
CNS & Neurological Disorders - Drug Targets The Emerging Role of MicroRNA in Schizophrenia
CNS & Neurological Disorders - Drug Targets Prostaglandin E Synthase: A Novel Drug Target for Inflammation and Cancer
Current Pharmaceutical Design Nanophytomedicine Based Novel Therapeutic Strategies in Liver Cancer
Current Topics in Medicinal Chemistry Analgesia in PACU: Intravenous Opioids
Current Drug Targets High Cytotoxicity and Apoptotic Effects of Natural Bioactive Benzofuran Derivative on the MCF-7 Breast Cancer Cell Line
Combinatorial Chemistry & High Throughput Screening Nuances in Alzheimer’s Genetic Risk Reveal Differential Predictions of Non-demented Memory Aging Trajectories: Selective Patterns by APOE Genotype and Sex
Current Alzheimer Research Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
CNS & Neurological Disorders - Drug Targets Historical Observations on the Discovery of Platelets, Platelet Function Testing and the First Antiplatelet Agent
Current Drug Targets Delirium Secondary to Lamotrigine Toxicity
Current Drug Safety 5-HT Receptor-Associated Protein Networks: New Targets for Drug Discovery in Psychiatric Disorders?
Current Drug Targets A Review of Herbal Remedies for Multiple Sclerosis-Like Disorders in Traditional Persian Medicine (TPM)
Current Drug Metabolism Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo
CNS & Neurological Disorders - Drug Targets Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?
Current Medicinal Chemistry Reconsidering the Scenario of Cyberbullying: Promoting the Internalization of the Locus of Control in Adolescents through Cognitive Restructuring
Adolescent Psychiatry